CDK4 and CDK6 kinases: From basic science to cancer therapy

A Fassl, Y Geng, P Sicinski - Science, 2022 - science.org
BACKGROUND Cyclins and cyclin-dependent kinases (CDKs) drive cell division. Of
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …

Treating cancer with selective CDK4/6 inhibitors

B O'leary, RS Finn, NC Turner - Nature reviews Clinical oncology, 2016 - nature.com
Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery
and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at …

Targeting CDK4 and CDK6: from discovery to therapy

CJ Sherr, D Beach, GI Shapiro - Cancer discovery, 2016 - AACR
Biochemical and genetic characterization of D-type cyclins, their cyclin D–dependent
kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16INK4 over two …

The history and future of targeting cyclin-dependent kinases in cancer therapy

U Asghar, AK Witkiewicz, NC Turner… - Nature reviews Drug …, 2015 - nature.com
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has
long been anticipated that our understanding of the basic principles of cell cycle control …

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

K Pandey, HJ An, SK Kim, SA Lee… - … journal of cancer, 2019 - Wiley Online Library
Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell
proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 …

Targeting cancer cell dormancy

A Recasens, L Munoz - Trends in pharmacological sciences, 2019 - cell.com
Cancer cell dormancy is a process whereby cells enter reversible cell cycle arrest, termed
quiescence. Quiescence is essential for cancer cells to acquire additional mutations, to …

[HTML][HTML] Glioblastoma targeted therapy: updated approaches from recent biological insights

M Touat, A Idbaih, M Sanson, KL Ligon - Annals of Oncology, 2017 - Elsevier
Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

[HTML][HTML] Targeting CDK4/6 in patients with cancer

E Hamilton, JR Infante - Cancer treatment reviews, 2016 - Elsevier
The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma
(Rb) pathway controls cell cycle progression by regulating the G1-S checkpoint …

[HTML][HTML] Novel insights into mesothelioma biology and implications for therapy

TA Yap, JG Aerts, S Popat, DA Fennell - Nature Reviews Cancer, 2017 - nature.com
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence
worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and …

Cell-cycle therapeutics come of age

M Ingham, GK Schwartz - Journal of Clinical Oncology, 2017 - ascopubs.org
The ability to sustain unscheduled proliferation is a hallmark of cancer. The normal process
of cell division occurs via the cell cycle, a series of highly regulated steps that are …